Spyre Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 19, 2026
SYRE$103.86+7.5%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Net loss | $(155,203) | $(208,018) | $(338,790) |
| Other comprehensive income (loss): | |||
| Foreign currency translation adjustment | (22) | 4 | 37 |
| Unrealized gain (loss) on marketable securities | 711 | (126) | 313 |
| Total comprehensive loss | $(154,514) | $(208,140) | $(338,440) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.